August 29, 2024
In the world of medical devices, particularly those categorized as moderate to high-risk, clinical data is a critical component of the regulatory approval process. This data, presented to regulatory authorities, forms the basis for marketing authorization in most jurisdictions.
The challenge lies in determining the adequacy of the available data and crafting a persuasive justification for its suitability. Let’s explore the criteria used to assess the suitability of three different categories of data.
The existence of published literature on a subject device, even in large quantities, may not be sufficient to support a particular marketing application. Several factors come into play:
While the FDA has published guidance on the use of RWE to support marketing applications, it remains more of a theoretical option than a practical one. Similarly, Notified Bodies (NBs) will rarely find RWE such as registry data sufficient to support EU certification.
Data originally collected for non-regulatory purposes – publication, product development, etc. – may not meet the requirements for use as supporting evidence for a regulatory submission. Before a decision is made to rely on such data, a thorough review of sponsor and site files should be conducted to ensure documentation is available to demonstrate:
Navigating the regulatory landscape for medical device approval is a complex process. Understanding the criteria for assessing the suitability of available data is crucial in crafting a compelling case for regulatory approval. By considering these factors, applicants can better position themselves for a successful regulatory outcome.
For the US market, device manufacturers should consider engaging FDA via the Q-Submission (QSub) process to obtain feedback directly from reviewers regarding suitability and sufficiency of their proposed clinical data strategy.
Ensuring your clinical data meets the stringent requirements for medical device approval can be a daunting task. Whether you’re navigating the complexities of published literature, real-world evidence, or previously conducted studies, ProPharma is here to help. Our team of experts can guide you through the regulatory maze, ensuring your data is robust, compliant, and persuasive. Contact us today to learn how we can support your medical device's path to market.
TAGS: Medical Devices Clinical Research Solutions MedTech Clinical Data
February 7, 2017
In October 2015, the FDA published a guidance document which outlines its recommendations regarding “the nonclinical evaluation of previously approved drug substances when a new formulation or a new...
October 7, 2020
In the era of technological disruption, data science is a disruptor for the books. Today’s data scientists develop processes, algorithms, and systems to mine structured and unstructured data with the...
July 12, 2021
Before using a significant risk medical device in a clinical study, Sponsors must first obtain FDA approval. Frequently, the request for an investigational device exemption (IDE) is disapproved, and...